Your browser doesn't support javascript.
Humoral Responses in the Omicron Era Following 3-Dose SARS-CoV-2 Vaccine Series in Kidney Transplant Recipients.
McEvoy, Caitríona M; Hu, Queenie; Abe, Kento T; Yau, Kevin; Oliver, Matthew J; Levin, Adeera; Gingras, Anne-Claude; Hladunewich, Michelle A; Yuen, Darren A.
  • McEvoy CM; St. Michael's Hospital Keenan Research Centre for Biomedical Science, Unity Health Toronto, Toronto, ON, Canada.
  • Hu Q; Division of Nephrology, Department of Medicine, St. Michael's Hospital, Unity Health Toronto, Toronto, ON, Canada.
  • Abe KT; Temerty Faculty of Medicine, University of Toronto, Toronto, ON, Canada.
  • Yau K; Lunenfeld-Tanenbaum Research Institute at Mount Sinai Hospital, Toronto, ON, Canada.
  • Oliver MJ; Lunenfeld-Tanenbaum Research Institute at Mount Sinai Hospital, Toronto, ON, Canada.
  • Levin A; Department of Molecular Genetics, University of Toronto, Toronto, ON, Canada.
  • Gingras AC; Temerty Faculty of Medicine, University of Toronto, Toronto, ON, Canada.
  • Hladunewich MA; Division of Nephrology, Department of Medicine, Sunnybrook Health Sciences Centre, Toronto, ON, Canada.
  • Yuen DA; Temerty Faculty of Medicine, University of Toronto, Toronto, ON, Canada.
Transplant Direct ; 9(1): e1401, 2023 Jan.
Article in English | MEDLINE | ID: covidwho-2161274
ABSTRACT
Kidney transplant recipients (KTRs) have a diminished response to SARS-CoV-2 vaccination compared with immunocompetent individuals. Deeper understanding of antibody responses in KTRs following third-dose vaccination would enable identification of those who remain unprotected against Omicron.

Methods:

We profiled antibody responses in KTRs pre- and at 1 and 3 mo post-third-dose SARS-CoV-2 mRNA-based vaccine. Binding antibody levels were determined by ELISA. Neutralization against wild type, Beta, Delta, and Omicron (BA.1) variants was determined using a SARS-CoV-2 spike-pseudotyped lentivirus assay.

Results:

Forty-four KTRs were analyzed at 1 and 3 mo (n = 26) post-third dose. At 1 mo, the proportion of participants with a robust antibody response had increased significantly from baseline, but Omicron-specific neutralizing antibodies were detected in just 45% of KTRs. Median binding antibody levels declined at 3 mo, but the proportion of KTRs with a robust antibody response was unchanged; 38.5% KTRs maintained Omicron-specific neutralization at 3 mo. No clinical variables were significantly associated with Omicron-neutralizing antibodies, but antireceptor binding domain titers appeared to identify those with Omicron-specific neutralizing capacity.

Conclusions:

Over 50% of KTRs lack Omicron-specific neutralization capacity 1 mo post-third mRNA-vaccine dose. Antibody levels of responders were well preserved at 3 mo. Anti receptor binding domain antibody titers may identify patients with a detectable Omicron-neutralizing antibody response.

Full text: Available Collection: International databases Database: MEDLINE Type of study: Prognostic study Topics: Vaccines / Variants Language: English Journal: Transplant Direct Year: 2023 Document Type: Article Affiliation country: TXD.0000000000001401

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Type of study: Prognostic study Topics: Vaccines / Variants Language: English Journal: Transplant Direct Year: 2023 Document Type: Article Affiliation country: TXD.0000000000001401